# VESIVAX TLR7 FORMULA

> **NIH NIH N01** · MOLECULAR EXPRESS, INC. · 2024 · $2,999,352

## Abstract

The contractor will develop ME-M-006 as a vaccine adjuvant.  ME-M-006 is composed of 1V209, a TLR7 agonist, formulated within the VesiVax liposomal platform.  The focus of the contract is the manufacturing optimization, stability testing, and product characterization processes, where the adjuvant will be evaluated within the context of vaccines to protect against Neisseria gonorrhoeae using the MtrE recombinant protein antigen, and Aspergillosis fumigatus using the Aspf9 recombinant protein antigen.

## Key facts

- **NIH application ID:** 11203954
- **Project number:** 75N93024C00017-0-9999-1
- **Recipient organization:** MOLECULAR EXPRESS, INC.
- **Principal Investigator:** Samon Ho
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $2,999,352
- **Award type:** —
- **Project period:** 2024-09-01 → 2027-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11203954

## Citation

> US National Institutes of Health, RePORTER application 11203954, VESIVAX TLR7 FORMULA (75N93024C00017-0-9999-1). Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/grant/nih/11203954. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*